Apurinic/apyrimidinic endonuclease 1 induced upregulation of fibroblast growth factor 2 and its receptor 3 induces angiogenesis in human osteosarcoma cells

Cancer Science

Volumn 105, Issue 2, 2014, Pages 186-194

  Ren, Tao ^a   Qing, Yi ^a   Dai, Nan ^a   Li, Mengxia ^a   Qian, Chengyuan ^a   Yang, Yuxin ^a   Cheng, Yi ^a   Li, Zheng ^a   Zhang, Shiheng ^a   Zhong, Zhaoyang ^a   Wang, Dong ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Microvessel density; Osteosarcoma; Tumor angiogenesis; Xenograft

Indexed keywords

ANGIOGENESIS INHIBITOR; APE1 SIRNA; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MATRIGEL; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC GENE THERAPY; ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CAPILLARY DENSITY; CHILD; CONTROLLED STUDY; FEMALE; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SCHOOL CHILD; TUMOR VOLUME; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; YOUNG ADULT;

CANCER; MICROVESSEL DENSITY; OSTEOSARCOMA; TUMOR ANGIOGENESIS; XENOGRAFT;

ADOLESCENT; ADULT; AGED; ANIMALS; BONE NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CHILD; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; DOWN-REGULATION; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROVESSELS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; OSTEOSARCOMA; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RNA, SMALL INTERFERING; UP-REGULATION; YOUNG ADULT;

EID: 84893754365     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12334     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006; 6: 1154-61.
3. Meyers PA, Gorlick R, Heller G et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 1998; 16: 2452-8.
4. Bacci G, Briccoli A, Longhi A et al. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol 2005; 44: 748-55.
5. Janeway KA, Barkauskas DA, Krailo MD et al. Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group. Cancer 2012; 118: 4597-605.
6. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
7. Blann AD, Ramcharan KS, Stonelake PS, Luesley D, Lip GY. The angiome: a new concept in cancer biology. J Clin Pathol 2011; 64: 637-43.
8. Tzeng HE, Tsai CH, Chang ZL et al. Interleukin-6 induces vascular endothelial growth factor expression and promotes angiogenesis through apoptosis signal-regulating kinase 1 in human osteosarcoma. Biochem Pharmacol 2013; 85: 531-40.
9. Minisini AM, Di Loreto C, Mansutti M et al. Topoisomerase IIα and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancer. Cancer Lett 2005; 224: 133-9.
10. Bajpai J, Sharma M, Sreenivas V et al. VEGF expression as a prognostic marker in osteosarcoma. Pediatr Blood Cancer 2009; 53: 1035-9.
11. Kelley MR, Georgiadis MM, Fishel ML. APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA Repair/Redox protein APE1/Ref-1. Curr Mol Pharmacol 2012; 5: 36-53.
12. Wang YT, Tzeng DW, Wang CY, Hong JY, Yang JL. APE1/Ref-1 prevents oxidative inactivation of ERK for G(1)-to-S progression following lead acetate exposure. Toxicology 2013; 305: 120-9.
13. Sultana R, McNeill DR, Abbotts R et al. Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors. Int J Cancer 2012; 131: 2433-44.
14. Wallace SS, Murphy DL, Sweasy JB. Base excision repair and cancer. Cancer Lett 2012; 327: 73-89.
15. Jiang A, Gao H, Kelley MR, Qiao X. Inhibition of APE1/Ref-1 redox activity with APX3330 blocks retinal angiogenesis in vitro and in vivo. Vision Res 2011; 51: 93-100.
16. Zou GM, Karikari C, Kabe Y, Handa H, Anders RA, Maitra A. The Ape-1/Ref-1 redox antagonist E3330 inhibits the growth of tumor endothelium and endothelial progenitor cells: therapeutic implications in tumor angiogenesis. J Cell Physiol 2008; 219: 209-18.
17. Tell G, Damante G, Caldwell D, Kelley MR. The intra-cellular localization of APE1/Ref-1: more than a passive phenomenon? Antioxid Redox Signal 2005; 7: 367-84.
18. Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 2004; 306: 1506-7.
19. Brown KC, Lau JK, Dom AM et al. MG624, an a7-nAChR antagonist, inhibits angiogenesis via the Egr-1/FGF2 pathway. Angiogenesis 2012; 15: 99-114.
20. Wang L, Park H, Chhim S et al. A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts. Mol Cancer Ther 2012; 11: 864-72.
21. Liekens S, Bronckaers A, Belleri M et al. The thymidine phosphorylase inhibitor 5′-O-tritylinosine (KIN59) is an antiangiogenic multitarget fibroblast growth factor-2 antagonist. Mol Cancer Ther 2012; 11: 817-29.
22. Hussain S, Slevin M, Matou S et al. Anti-angiogenic activity of sesterterpenes; natural product inhibitors of FGF-2-induced angiogenesis. Angiogenesis 2008; 11: 245-56.
23. Oneyama C, Ikeda J, Okuzaki D et al. MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways. Oncogene 2011; 30: 3489-501.
24. Wang D, Luo M, Kelley MR. Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol Cancer Ther 2004; 3: 679-86.
25. Wang D, Zhong ZY, Li MX, Xiang DB, Li ZP. Vector-based Ape1 small interfering RNA enhances the sensitivity of human osteosarcoma cells to endostatin in vivo. Cancer Sci 2007; 98: 1993-2001.
26. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980; 153: 106-20.
27. Ross FG. Osteogenic sarcoma. Br J Radiol 1964; 37: 259-76.
28. Zhou B, Ma R, Si W et al. MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth. Cancer Lett 2013; 333: 159-69.
29. Xiang DB, Chen ZT, Wang D et al. Chimeric adenoviral vector Ad5/F35-mediated APE1 siRNA enhances sensitivity of human colorectal cancer cells to radiotherapy in vitro and in vivo. Cancer Gene Ther 2008; 15: 625-35.
30. Yamato I, Sho M, Shimada K et al. PCA-1/ALKBH3 contributes to pancreatic cancer by supporting apoptotic resistance and angiogenesis. Cancer Res 2012; 72: 4829-39.
31. Lai KB, Sanderson JE, Yu CM. The regulatory effect of norepinephrine on connective tissue growth factor (CTGF) and vascular endothelial growth factor (VEGF) expression in cultured cardiac fibroblasts. Int J Cardiol 2013; 163: 183-9.
32. Azuma K, Kawahara A, Hattori S et al. NDRG1/Cap43/Drg-1 may predict tumor angiogenesis and poor outcome in patients with lung cancer. J Thorac Oncol 2012; 7: 779-89.
33. Fagiani E, Christofori G. Angiopoietins in angiogenesis. Cancer Lett 2013; 328: 18-26.
34. Cun Y, Dai N, Xiong C et al. Silencing of APE1 enhances sensitivity of human hepatocellular carcinoma cells to radiotherapy in vitro and in a xenograft model. PLoS ONE 2013; 8: e55313. doi:10.1371/journal.pone.0055313.
35. Jin Y, Sheikh F, Detillieux KA, Cattini PA. Role for early growth response-1 protein in alpha(1)-adrenergic stimulation of fibroblast growth factor-2 promoter activity in cardiac myocytes. Mol Pharmacol 2000; 57: 984-90.
36. Jimenez SK, Sheikh F, Jin Y et al. Transcriptional regulation of FGF-2 gene expression in cardiac myocytes. Cardiovasc Res 2004; 62: 548-57.